ROCKET PHARMACEUTICALS, INC. — Form 8-K
Filed August 27, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 32/100
What the filing says
Rocket Pharmaceuticals filed an 8-K on 2026-08-27 reporting Item 5.02 disclosures regarding departure of director(s) or officer(s) and compensatory arrangements. The filing header indicates these items are present but the specific names, dates, dollar amounts, equity grants, severance terms, or other material details are not provided in the accessible text—only the document structure and filing metadata are visible.
Why this rating
Leadership transitions routine unless quantified impact disclosed; lacks specifics (names, amounts, terms) to assess materiality relative to $212.5M market cap.
Extracted items
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.